Obstructive Sleep Apnea

The results show melatonin levels or phases relative to clock time were not different between healthy individuals and patients with obstructive sleep apnea.

The rate of sleep apnea is greater in patients with bipolar disorder and depression.

Results from the analysis suggest participants treated for previously diagnosed obstructive sleep apnea experience a significantly higher risk of having RPD coexistent with AMD.

Promising results from the ATS Conference suggest that AD109, an oral treatment for obstructive sleep apnea, demonstrated significant reduction of AHI and potential mitigation of daytime fatigue.

AD109 shows the potential to address an unmet need in obstructive sleep apnea treatment.

Results from the NIH RECOVER Initiative study show an 89% risk of long COVID in women with sleep apnea and 59% in men when compared with adults without the condition.

Women with obstructive sleep apnea show increased extracellular water and decreased intracellular water and phase angle compared with men before treatment with CPAP.

In patients hospitalized with acute coronary syndrome and metabolic syndrome, obstructive sleep apnea was associated with an increased risk of major adverse cardiovascular and cerebrovascular events in women, but not in men.

Compared with nasal masks, oronasal masks are associated with a more collapsible upper airway, requiring higher therapeutic CPAP levels, according to the study.

The longitudinal study finds prevalent obstructive sleep apnea, insomnia, and sleepiness could differentially mediate or moderate the effect of multiple sclerosis on cognition.

Practicing oral hygiene improves health issues from gum disease to cardiac disease, and Lebovic believes nasal hygiene can have that impact as well.

Patients with with depression and AHI ≥ 30 show the greatest risk of all-cause mortality.

The study evaluated how intranasal mometasone furoate affected sleep-disordered breathing symptoms and patient quality of life by comparing its efficacy to intranasal saline in the pediatric patients.

The daytime-nighttime appliance named DNA, serves as a novel alternative to existing treatment options for mild-to-moderate obstructive sleep apnea.

Results indicated similar outcomes between those who underwent tonsillectomy and mUPPP, with minor differences favoring the tonsillectomy group.